Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2022-09-01
2024-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brief Enhanced Anxiety Sensitivity Treatment (Group)
NCT05458362
Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
NCT01766401
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
NCT01629966
Reducing Anxiety and Stress in Primary Care Patients
NCT03794089
Attention Bias Modification for Anxiety: A Randomized Control Trial With Biomarkers
NCT02200003
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Veterans will be enrolled following informed consent. The research staff will read the measures to the Veteran who will verbally provide their answers.
Veterans will next complete the baseline assessment. At the baseline assessment, Veterans meet with the Project Coordinator by phone or virtually to complete a consenting process, guidance on the video software being used, and set-up and guidance on use of the mobile app.
Following the baseline assessment, participants will be scheduled to receive the face-to-face virtual intervention followed by two weeks of EMA/EMI via mPRO.
At the end of the two weeks, Veterans will complete a post-intervention assessment appointment. The post-intervention assessment includes an exit interview for participants to provide additional feedback regarding acceptability of the intervention.
Follow-up assessment appointments will be completed at the 1-month and 3-month follow-ups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BEAST Condition
A one-session intervention that can be delivered effectively by a clinician via telehealth and supplemented with a mobile app to provide opportunities to practice the skills learned in the face-to-face session.
Brief Enhanced Anxiety Sensitivity Treatment
BEAST is a CBT-based intervention that includes psychoeducation, identifying and challenging maladaptive thoughts, and interoceptive exposure. The intervention is delivered through a single virtual face-to-face session supplemented with a mobile app for two weeks after the face to face session.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brief Enhanced Anxiety Sensitivity Treatment
BEAST is a CBT-based intervention that includes psychoeducation, identifying and challenging maladaptive thoughts, and interoceptive exposure. The intervention is delivered through a single virtual face-to-face session supplemented with a mobile app for two weeks after the face to face session.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Score equal to or greater than 9 on the SSASI indicating elevated anxiety sensitivity
* Score equal to or greater than 5 on the WHODAS 2.0
Exclusion Criteria
* Orientation-Memory-Concentration Test
* Veterans without access to a smartphone
* Veterans with significant medical or psychiatric conditions that may limit participation, including:
* severe documented schizophrenia
* an ongoing active psychotic or manic state
* an imminent suicide crisis will be excluded from our study and provided the appropriate referral
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicholas P Allan, PhD
Role: PRINCIPAL_INVESTIGATOR
VA Finger Lakes Healthcare System, Canandaigua, NY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Finger Lakes Healthcare System, Canandaigua, NY
Canandaigua, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I02RX003880
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
D3880-P
Identifier Type: -
Identifier Source: org_study_id
NCT05490199
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.